

|                          |  | Teaching           | Guide               |                              |                                     |  |
|--------------------------|--|--------------------|---------------------|------------------------------|-------------------------------------|--|
|                          | Identifyin   | g Data             |                     |                              | 2021/22                             |  |
| Subject (*)              | Medicinal Chemistry  |                    |                     | Code                         | 610509116                           |  |
| Study programme          | Mestrado Universitario en Investig   | gación Química     | ustrial (Plan 2020) |                              |                                     |  |
|                          |  | Descrip            | otors               |                              |                                     |  |
| Cycle                    | Period   | Yea                | ır                  | Туре                         | Credits                             |  |
| Official Master's Degree | e 2nd four-month period  | Firs               | st                  | Optional                     | 3                                   |  |
| Language                 | SpanishEnglish   |                    |                     |                              |                                     |  |
| Teaching method          | Face-to-face   |                    |                     |                              |                                     |  |
| Prerequisites            |  |                    |                     |                              |                                     |  |
| Department               | Departamento profesorado máste   | rQuímica           |                     |                              |                                     |  |
| Coordinador              | Riveiros Santiago, Ricardo   |                    | E-mail              | ricardo.riveiros@            | udc.es                              |  |
| Lecturers                | Brea Fernández, Roberto Javier   |                    | E-mail              | roberto.brea@uc              | lc.es                               |  |
|                          | Criado Fernández, Alejandro  |                    |                     | a.criado@udc.es              |                                     |  |
|                          | Riveiros Santiago, Ricardo   |                    |                     | ricardo.riveiros@            | udc.es                              |  |
| Web                      | http://www.usc.es/gl/centros/quim  | ica/curso/maste    | er.html             |                              |                                     |  |
| General description      | This subject aims that the student   | s acquire the ba   | asic concepts in    | n the field of medicinal che | emistry and drug design, and also   |  |
|                          | know the required steps for drug of  | development, ra    | nging from the      | discovery of an active cor   | npound in the laboratory to its     |  |
|                          | integration into the market. The su  | ubject will also a | ddress the ma       | jor current methodologies    | in finding lead compounds that      |  |
|                          | are employed in both industrial an   | d academic leve    | el, and its optir   | nization for the developme   | ent of a drug. This includes from   |  |
|                          | structure-based desigh, virtual screening, to fragment-based design of compounds. The most relevant aspects in the         |                    |                     |                              |                                     |  |
|                          | quantification oof the structure-relationships (QSAR) will be also described. Each of the contents of this subject will be |                    |                     |                              |                                     |  |
|                          | illustrated by representative examples.  |                    |                     |                              |                                     |  |
| Contingency plan         | 1. Modifications to the contents   |                    |                     |                              |                                     |  |
|                          | - There are no modifications.  |                    |                     |                              |                                     |  |
|                          | 2. Methodologies   |                    |                     |                              |                                     |  |
|                          | *Teaching methodologies that are   | maintained         |                     |                              |                                     |  |
|                          | - All teaching methodologies are r   | maintained (mag    | gisterial session   | n, seminars and objective    | test).                              |  |
|                          | *Teaching methodologies that are   | modified           |                     |                              |                                     |  |
|                          | The teaching methodologies will b  | e adapted to the   | e hybrid modal      | ity:                         |                                     |  |
|                          | - The master sessions and semina   | ars will be held s | synchronously       | at the time established in   | the calendar of activities, through |  |
|                          | the Teams platform.  |                    |                     |                              | -                                   |  |
|                          | -The objective test will be carried  | out through the    | Moodle and Te       | eams platforms at the time   | established in the activity         |  |
|                          | calendar.  | C C                |                     |                              |                                     |  |
|                          | 3. Mechanisms for personalized a   | ttention to stude  | ents                |                              |                                     |  |
|                          | 4. Modifications in the evaluation   |                    |                     |                              |                                     |  |
|                          | *Evaluation observations:  |                    |                     |                              |                                     |  |
|                          | 5. Modifications to the bibliography or webgraphy  |                    |                     |                              |                                     |  |

|      | Study programme competences / results  |  |  |
|------|--|--|--|
| Code | Study programme competences / results  |  |  |
| A1   | Define concepts, principles, theories and specialized facts of different areas of chemistry.             |  |  |
| A2   | Suggest alternatives for solving complex chemical problems related to the different areas of chemistry.  |  |  |
| A3   | 3 Innovate in the methods of synthesis and chemical analysis related to the different areas of chemistry |  |  |
| A4   | Apply materials and biomolecules in innovative fields of industry and chemical engineering.              |  |  |



| B1  | Possess knowledge and understanding to provide a basis or opportunity for originality in developing and / or applying ideas, often within a |
|-----|---|
|     | research context  |
| B2  | Students should apply their knowledge and ability to solve problems in new or unfamiliar environments within broader (or multidisciplinary) |
|     | contexts related to their field of study.   |
| B4  | Students should be able to communicate their conclusions, and the knowledge and the reasons that support them to specialists and            |
|     | non-specialists in a clear and unambiguous manner   |
| B7  | Identify information from scientific literature by using appropriate channels and integrate such information to raise and contextualize a   |
|     | research topic  |
| B10 | Use of scientific terminology in English to explain the experimental results in the context of the chemical profession                      |
| B11 | Apply correctly the new technologies to gather and organize the information to solve problems in the professional activity.                 |
| C1  | CT1 - Elaborar, escribir e defender publicamente informes de carácter científico e técnico  |
| C3  | CT3 - Traballar con autonomía e eficiencia na práctica diaria da investigación ou da actividade profesional.                                |
| C4  | CT4 - Apreciar o valor da calidade e mellora continua, actuando con rigor, responsabilidade e ética profesional.                            |

| Learning outcomes  |      |          |      |
|--|------|----------|------|
| Learning outcomes  | Stud | y progra | imme |
|  | cor  | npetenc  | es/  |
|  |      | results  |      |
| To know the main concepts in medicinal chemistry and drug design: therapeutic targets, enzimatic inhibitors, agonists,             | AC1  | BC1      | CC1  |
| antagonists, optimal pharmacological properties, etc.  | AC2  | BC2      | CC3  |
|  | AC3  | BC4      | CC4  |
|  | AC4  | BC7      |      |
|  |      | BC10     |      |
|  |      | BC11     |      |
| To know the required steps for drug development, starting from the discovery of an active compound in the laboratory till its      | AC1  | BC1      | CC1  |
| integration into the market.   | AC2  | BC2      | CC3  |
|  | AC3  | BC4      | CC4  |
|  | AC4  | BC7      |      |
|  |      | BC10     |      |
|  |      | BC11     |      |
| To know the main methodologies for the seaching of active molecules (hits) and their optimization for the development of a         | AC1  | BC1      | CC1  |
| new drug. Since the design based on the 3D structure of the therapeutic target, the real and virtual screening of libraries or the | AC2  | BC2      | CC3  |
| fragment based design.   | AC3  | BC4      | CC4  |
|  | AC4  | BC7      |      |
|  |      | BC10     |      |
|  |      | BC11     |      |

| Contents   |   |  |
|--|---|--|
| Торіс  | Sub-topic   |  |
| Chapter 1. General aspects, definitions and concepts | Drug discovery: historical perspective. Drug activity phases. Enzymatic catalysis.      |  |
|  | Definitions and concepts: agonist, antagonist, transition state analogs, reversible     |  |
|  | inhibition (competitive, non-competitive), irreversible inhibition, suicide substrates. |  |
|  | Examples.   |  |
| Chapter 2. Therapeutic targets                       | Therapeutic targets: classification and their main characteristics. Enzymes. Membrane   |  |
|  | transporters. Voltage-gated ion channels. Non-selective cation channels. Receptors      |  |
|  | with intrinsic ion channels. Receptors with intrinsic enzymatic activity. Receptors     |  |
|  | coupled to various cytosolic proteins. G-protein-coupled receptors. Nuclear receptors.  |  |



| Chapter 3. Strategies for drug discovery I. Structure-based    | Evolution of the structure-based design in drug discovery. Practical aspects of the    |
|--|--|
| design   | determination of the three dimensional structure of a target-X-ray crystallography for |
|  | the structure-based design. Applications of NMR spectroscopy in the rational design.   |
|  | Docking. Molecular dynamics simulations. QM/MM. Examples.                              |
| Chapter 4. Strategies for drug discovery II. Virtual screening | Basics of the virtual screening candidates. Available databases. Applications:         |
| and fragment-based design                                      | identifying ligands for a target or potential targets of a ligand. Basics of the       |
|  | fragment-based design. Screening of candidates by X-ray crystallography. Other         |
|  | biophysical screening methods. Examples.   |
| Chapter 5. Hit Compound optimization. QSAR studies             | Molecular modifications based on isosteric replacement. Conformational restriction     |
|  | and steric hindrance in medicinal chemistry. Homo and heterodimeric ligands.           |
|  | Prodrugs. Quantification of Structure-Activity Relationship (QSAR).                    |

|  | Plannin                 | g                       |                           |             |
|--|-------------------------|-------------------------|---------------------------|-------------|
| Methodologies / tests                                | Competencies /          | Teaching hours          | Student?s personal        | Total hours |
|  | Results                 | (in-person & virtual)   | work hours                |             |
| Guest lecture / keynote speech                       | A1 A2 A4 A3 B1 B2       | 12                      | 29                        | 41          |
|  | B4 B7 B10 B11           |                         |                           |             |
| Seminar  | A1 A2 A4 A3 B1 B2       | 7                       | 18                        | 25          |
|  | B4 B7 B10 B11           |                         |                           |             |
| Objective test                                       | A1 A4 A3 B1 B10         | 2                       | 5                         | 7           |
| Personalized attention                               |                         | 2                       | 0                         | 2           |
| (*)The information in the planning table is for guid | dance only and does not | take into account the l | heterogeneity of the stud | dents.      |

|                 | Methodologies  |
|-----------------|--|
| Methodologies   | Description  |
| Guest lecture / | It will be held 12 sessions of lectures by videoconference in one group, where the theoretical contents of the course will be    |
| keynote speech  | associated with illustrative examples. It will consist mainly in PowerPoint presentations. Copies of these presentations will be |
|                 | available for the students in advance via the Moodle platform of the course. This will allow the students to study ahead the     |
|                 | contents of the course and to facilitate the monitoring of explanations.   |
| Seminar         | Seven sessions in small group seminars are scheduled. In these seminars, students will solve practical exercises                 |
|                 | (interpretation and processing information using specialized software and internet, evaluation of scientific papers, etc.), will |
|                 | prepare reports related to the different subjects and will present them during the class, followed by a discussion section with  |
|                 | the professor and the rest of students. Students will have in advance the information they need via the Moodle platform.         |
|                 | Attendance at these classes is mandatory.  |
| Objective test  | It will be an objective test that will cover the entire contents of the subject.   |

Personalized attention

Methodologies

Description



| Seminar | Students must review the theoretical concepts introduced in each chapter using the reference manual and the material   |
|---------|--|
|         | provided by the professor. Those students, which have significant difficulties to do the proposed activities, should contact with  |
|         | the professor during the tutorials, in order to analyze the problems and to receive the necessary support.   |
|         | The professor will analyze with those students who do not successfully pass the evaluation, and so wish, their difficulties in learning the course content. Additional material (questions, exercises, tests, etc.) to strengthen the learning of the course might also provided.  |
|         | Students with appreciation a part-time academic and attendance waiver of exemption may complete the seminars in individual and/or group tutoring schedule to be agreed with the teachers. The activities undertaken in these tutorials will be similar to those of students in ordinary regime and consideration for the final assessment. |

|                              |                   | Assessment  |               |  |
|------------------------------|-------------------|---|---------------|--|
| Methodologies Competencies / |                   | Description   | Qualification |  |
|                              | Results           |   |               |  |
| Seminar                      | A1 A2 A4 A3 B1 B2 | Continuous assessment will be the 40% of the final assessment of the subject. It will   | 40            |  |
|                              | B4 B7 B10 B11     | have two components: interactive classes in small group (seminars) and interactive      |               |  |
|                              |                   | classes in very small group (tutorials). Seminars and tutorials will include solving of |               |  |
|                              |                   | proposed exercises and practical cases (10%), writing reports (10%), oral               |               |  |
|                              |                   | presentations [(works, reports, problems, practical cases), 10%] and oral questions     |               |  |
|                              |                   | along the course (10%).   |               |  |
| Objective test               | A1 A4 A3 B1 B10   | The objective test will focus on the entire contents of the subject.                    | 60            |  |

Assessment comments

The student's final qualification will be calculated applying this formula:

Final qualification = 0.4 x N1 + 0.6 x N2

N1 is the numeric qualification corresponding to the continuous assessment (scale 0-10) and N2 is the numeric qualification corresponding to the objective test (scale 0-10).

To access to the objective test the student must assist in, at least, 80% of the mandatory classroom teaching activities (seminars and tutorials).

| Students who study the subject for a second time will have the same system of class attendance and assestment than those who study the | course for |
|--|------------|
| first time.  |            |

In the case of students with recognition of part-time dedication and academic assistance waiver, the qualification of the continuous assessment will be replaced by that obtained in the personal tutorials.

Students who attend fewer than 25% of planned academic activities and do not assist to the objective test, will be qualified as "Not presented".

| Sources of information |   |  |
|------------------------|---|--|
| Basic                  | - Camille Georges Wermuth (2008). The practice of medicinal chemistry, 3rd Ed. Amsterdam: Elsevier          |  |
|                        | - Graham L. Patrick (2013). An introduction to medicinal chemistry, 5th Ed. Oxford: Oxford University Press |  |



| Complementary | - E. J. Corey, B. Czakó, L. Kürti (2007). Molecules and medicine. New Jersey: John Wiley and Sons                |
|---------------|--|
|               | - K. C. Nicolaou, T. Montagnon, Eds. (2008). Molecules that changed the world. Weinheim: Wiley-VCH               |
|               | - Edward R. Zartler & amp; Michael J. Shapiro, Eds. (2008). Fragment-based drug discovery, a practical approach. |
|               | Chichester: John Wiley & amp; amp; Sons  |
|               | - Celerino Abad Zapatero (2013). Ligand efficiency indices for drug discovery. Amsterdam: Elsevier               |

Recommendations

/

Subjects that it is recommended to have taken before

Subjects that are recommended to be taken simultaneously

Subjects that continue the syllabus

Other comments

Basic knowledge in the visiualization of the three dimensional structure of biomolecules using visualization programs such as Pymol, Mercury, etc. Management of databases such as Protein Data Bank (PDB), Expasy, etc. is also recommended.

(\*)The teaching guide is the document in which the URV publishes the information about all its courses. It is a public document and cannot be modified. Only in exceptional cases can it be revised by the competent agent or duly revised so that it is in line with current legislation.